The WSJ discusses Big Pharma lobbyist Billy Tauzin and the industry’s $80 billion in “protection money.” You’d think that might cause some concern in the K Street corridor that Mr. Tauzin inhabits. Nope. In spite of the double-cross, the drug makers say they are still planning to spend some $150 million through autumn on a […]